绥美凯的疗效如何呢？

(Dolutegravir tablets) is a compound preparation. Each tablet contains dolutegravir sodium (calculated as dolutegravir) 50 mg, abacavir sulfate (calculated as abacavir) 600 mg and lamivudine 300 mg. Clinically, it is suitable for the treatment of adults infected with human immunodeficiency virus (HIV) and adolescents over 12 years old (with a minimum weight of 40 kg). In 2015, Suimeikai (Dolutea Balamib Tablets) submitted a clinical application in China; on January 20, 2017, it applied for import and was granted priority review status; on August 1, 2017, the State Food and Drug Administration (CFDA) approved the new compound preparation Suimeike (Dolutea Abalamid Tablets) for the treatment of AIDS to enter China.

What is the efficacy of Suimeikai?

Dolutegravir, the active ingredient in Suimeike (Dolutea Balamib Tablets), can inhibit HIV integrase by binding to the active site of integrase and blocking the strand transfer step of reverse transcription deoxyribonucleic acid (DNA) integration (a key step in the HIV replication cycle). The other active ingredient, abacavir, is a carbocyclic synthetic nucleoside analog. Abacavir is converted into the active metabolite carbavir triphosphate (CBV-TP) under the action of intracellular enzymes, which is a deoxyguanosine-5'-triphosphate (dGTP) analog. CBV-TP inhibits the activity of HIV-1 reverse transcriptase (RT) by competing with the natural substrate dGTP and inserting into viral DNA. Another active ingredient, lamivudine, is a synthetic nucleoside analog. Lamivudine is phosphorylated in cells to generate an active 5-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The main mode of action of 3T-CTP is to terminate DNA chain synthesis by inserting nucleotide analogs, thereby inhibiting RT activity. The mechanism of action of Suimeikan can be said to directly reach the focus of the disease, and the curative effect is also very significant. However, there is no accurate data on how long one can live after taking Suimeike. It varies according to the patient's system and the degree of disease progression.

For adults and adolescents, the recommended dose is one tablet once daily. Adults or adolescents whose body weight is less than 40 kg should not be given this product because this product is a fixed-dose tablet and the dose cannot be reduced. Dolutegravir is a fixed-dose tablet and should not be used in patients requiring dose adjustments. If discontinuation or dose adjustment of one of the active ingredients is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these circumstances, physicians should refer to the respective product information for these medicines. If the patient misses a dose of Docetaxel, and it is more than 4 hours before the next dose, Docetaxel should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.